Project Grant K99DK142197
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$208K
Funding Federal Agency
National Institute of Neurological Disorders and Stroke
Awarding Federal Agency
National Institute of Diabetes and Digestive and Kidney Diseases
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award, totaling $5,666,172, was issued by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award aims to study the role of Schwann cell dysfunction and signaling pathways in the development of chemotherapy-induced painful peripheral neuropathy (CIPPN). Key objectives include examining the impact of peroxisome proliferator-activated receptor gamma (PPARγ) and low-density lipoprotein...
This $437,250 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to compare the gene expression of the key cell types that form the blood-nerve barrier (BNB) in the peripheral nervous system and the blood-brain barrier (BBB) in the central nervous system under physiological conditions. The research will also...
The University of California, San Diego (UCSD) was awarded a $434,500 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The funding will support research to investigate the regulation of Schwann cell mitochondria homeostasis and its role in painful peripheral neuropathy. Specifically, the project aims to examine how the low-density lipoprotein...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research aimed at correcting pathophysiological myelin formation in hereditary neuropathies. The $352,073 award, effective January 1, 2025 through December 31, 2025, will fund rigorous in vivo testing of an experimental ABCA1 agonist drug in validated mouse models of...
This Project Grant award, valued at $816,554.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279). The award aims to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) that replicates tumor growth, surgical resection, and treatment with an oxaliplatin-based chemotherapy regimen. The research will assess the impact of surgery and tumor growth on the...
This $499,979 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to uncover the role of astrocytes, a type of glial cell, in the development and treatment of neuropathic pain. The 5-year project aims to: 1) determine how peripheral nerve injury alters dorsal horn astrocyte function, 2) elucidate how targeted...
This federal Project Grant award for $387,500.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop novel small molecule inhibitors of the EphB1/2 tyrosine kinase as a potential non-opioid treatment for peripheral neuropathic pain. The overarching goal is to pharmacologically examine whether selective EphB1 tyrosine kinase inhibition can reverse...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $144,362 to Drexel University to investigate the role of the PERK kinase in regulating the localization of neuroprotective growth factors in neurons. The 2-year and 7-month project, which began on July 17, 2024, aims to define how PERK interacts with the CaMKII kinase to...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $459,111 to the University of Tennessee Health Science Center to investigate a novel pharmacological approach to stroke neuroprotection in diabetic patients. The research aims to explore the beneficial effects and underlying mechanisms of a newly developed small molecular...